Skip to content
  1. Home
  2. Sexual health
  3. Gonadorelin acetate

Sexual health

Gonadorelin acetate

GnRH agonist peptide that stimulates endogenous LH and FSH to preserve testicular function and fertility during testosterone replacement therapy.

FDA approved Sexual health

Reviewed 2026-09-12
Full name
Gonadotropin-releasing hormone (GnRH) decapeptide acetate
Also known as
GnRH, LHRH, luliberin
Regulatory status
FDA approved | Off-label: HPG-axis preservation during TRT

Origin

A synthetic decapeptide copy of endogenous GnRH, FDA-approved since 1981 for evaluating gonadotropin reserve and treating hypogonadotropic hypogonadism. Increasingly used off-label to prevent testicular suppression from exogenous testosterone.

Mechanism

Agonizes GnRH receptors on pituitary gonadotrophs, stimulating LH and FSH release. Pulsatile dosing maintains HPG-axis output; continuous exposure paradoxically suppresses it, the basis of medical castration. In TRT-suppressed men, pulsatile/low-dose gonadorelin restimulates endogenous testosterone and spermatogenesis.

Research summary

Evidence

A 2026 narrative review identified GnRH-based strategies as promising for TRT-induced reproductive suppression, though evidence for full spermatogenesis/fertility restoration remains limited. Small studies show combination therapy (TRT + low-dose gonadorelin + hCG) partially restores FSH/LH and reduces testicular atrophy, with variable success.

Evidence tier: FDA approved — see the methodology note for how this is assessed.

Citations

Reported benefits

  • preservation/restoration of endogenous testosterone in TRT users
  • maintenance of spermatogenesis during TRT
  • reduced testicular atrophy

Dosing protocols reported in the literature & community

These are protocols reported by compounding pharmacies, published trials, or self-experimentation communities — not a prescription. Start low, especially for anything new.

Reported dosing protocols
RouteReported protocol
Subcutaneous or intravenous injectionOff-label TRT protocol: ~150 mcg subcutaneous twice weekly, or pulsatile pump dosing; not well standardized.

Side effects

  • local injection-site reactions
  • transient nausea and headache
  • gynecomastia
  • mood changes

Safety notes

Safety: Generally well-tolerated at low/pulsatile dosing. Continuous high-dose agonism causes prolonged suppression. Pulsatile administration is critical to avoid paradoxical effects. Caution with pituitary pathology.
Community & reddit notes (anecdotal — not clinical evidence)

TRT users report using low-dose gonadorelin alongside testosterone to maintain the HPG axis and fertility, often combined with hCG and clomiphene. Reported outcomes are variable.